Blass, Benjamin E. published the artcileDesign, synthesis, and evaluation of functionalized 5-(4-arylpiperazin-1-yl)-N-arylpentanamides as selective dopamine D3 receptor ligands, Quality Control of 178928-58-0, the publication is Medicinal Chemistry Research (2022), 31(1), 132-145, database is CAplus.
Substance use disorder remains a major, unmet medical need. Cocaine is one of the most commonly abused recreational drugs and in 2018, there were over 5.5 million cocaine users. There are no approved therapies for the treatment of cocaine use disorder, but the D3 dopamine receptor has been identified as a potential therapeutic target. Our initial lead compound (6) is a potent D3 ligand with a high level of selectivity for D3 over D2, but its solubility is low. We have identified a new series of functionalized 5-(4-arylpiperazin-1-yl)-N-arylpentanamides (7) that are potent D3 binders that have moderate to high selectivity for D3 over D2. Exemplary members of this series were also significantly more soluble than our initial lead compound (6).
Medicinal Chemistry Research published new progress about 178928-58-0. 178928-58-0 belongs to piperazines, auxiliary class Piperazine,Nitrile,Benzene, name is 1-(3-Cyanophenyl)piperazine, and the molecular formula is C11H13N3, Quality Control of 178928-58-0.
Referemce:
https://en.wikipedia.org/wiki/Piperazine,
Piperazines – an overview | ScienceDirect Topics